Stryker Corporation (SYK)

Currency in USD
389.06
-4.10(-1.04%)
Real-time Data·
SYK Scorecard
Full Analysis
Has raised its dividend for 15 consecutive years
SYK is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
388.11392.50
52 wk Range
329.16406.19
Key Statistics
Prev. Close
393.15
Open
391.2
Day's Range
388.11-392.5
52 wk Range
329.16-406.19
Volume
255.47K
Average Volume (3m)
1.22M
1-Year Change
11.3%
Book Value / Share
55.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SYK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
432.27
Upside
+11.11%
Members' Sentiments
Bearish
Bullish
ProTips
15 analysts have revised their earnings upwards for the upcoming period

Stryker Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Stryker Corporation Company Profile

Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, cranial, and maxillofacial and chest wall devices, as well as dural substitutes and sealants; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries; thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Stryker Corporation SWOT Analysis


Financial Prowess
Stryker's robust financial health, consistent revenue growth, and strategic acquisitions position it as a formidable player in the medical technology secto
Market Expansion
Delve into Stryker's entry into the $15 billion venous thromboembolism market through its Inari Medical acquisition, potentially driving substantial future growth
Innovation Leade
Explore how Stryker's focus on robotics and advanced medical technologies, particularly its Mako system, is reshaping orthopedic surgery and market dynamics
Analyst Outlook
With price targets ranging from $420 to $450, analysts remain bullish on Stryker's prospects, despite challenges like tariff impacts and integration risks
Read full SWOT analysis

Stryker Corporation Earnings Call Summary for Q2/2025

  • Stryker Q2 2025 EPS of $3.13 beat $3.07 forecast; revenue of $6.02B exceeded $5.94B estimate; organic sales grew 10.2%
  • Full-year 2025 guidance raised: organic net sales growth now 9.5-10%, adjusted EPS $13.4-$13.6; strong growth in robotic procedures expected
  • Stock declined 1.92% to $400.41 despite earnings beat; slight recovery in aftermarket trading to $401.95
  • CEO highlighted leadership in orthopedic robotics; plans to expand product offerings with Mako Spine and Shoulder systems
  • Challenges include supply chain disruptions, market saturation, and regulatory changes in international markets
Last Updated: 01/08/2025, 01:08
Read Full Transcript

Compare SYK to Peers and Sector

Metrics to compare
SYK
Peers
Sector
Relationship
P/E Ratio
51.1x14.2x−0.6x
PEG Ratio
−3.260.450.00
Price/Book
7.0x2.3x2.6x
Price / LTM Sales
6.3x1.7x3.3x
Upside (Analyst Target)
11.4%64.2%38.7%
Fair Value Upside
Unlock9.5%5.1%Unlock

Analyst Ratings

21 Buy
9 Hold
1 Sell
Ratings:
31 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 432.27
(+11.11% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 7.65%
Dividend Yield
0.85%
Industry Median 1.31%
Annualised payout
3.36
Paid quarterly
5-Years Growth
+8.14%
Growth Streak

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
3.13 / 3.07
Revenue / Forecast
6.02B / 5.94B
EPS Revisions
Last 90 days

SYK Income Statement

People Also Watch

206.57
ABBV
-0.72%
365.66
SHW
-0.47%
91.87
MDT
-0.20%
304.15
ADP
+0.35%
175.53
JNJ
-0.71%

FAQ

What Stock Exchange Does Stryker Trade On?

Stryker is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Stryker?

The stock symbol for Stryker is "SYK."

What Is the Stryker Market Cap?

As of today, Stryker market cap is 148.63B.

What Is Stryker's Earnings Per Share (TTM)?

The Stryker EPS (TTM) is 7.65.

When Is the Next Stryker Earnings Date?

Stryker will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is SYK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Stryker Stock Split?

Stryker has split 9 times.

How Many Employees Does Stryker Have?

Stryker has 53000 employees.

What is the current trading status of Stryker (SYK)?

As of 28 Aug 2025, Stryker (SYK) is trading at a price of 389.06, with a previous close of 393.15. The stock has fluctuated within a day range of 388.11 to 392.50, while its 52-week range spans from 329.16 to 406.19.

What Is Stryker (SYK) Price Target According to Analysts?

The average 12-month price target for Stryker is USD432.27037, with a high estimate of USD465 and a low estimate of USD316. 21 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +11.11% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.